US Dollar vs Yen

登録して無料でリアルタイムの株価、インタラクティブチャート、ライブオプションフローなどを入手してください。

登録

ホーム
投資
株式
アメリカ
NASDAQ
Ultragenyx Pharmaceutical Inc (RARE)
Ultragenyx Pharmaceutical Inc (RARE) ニュース

RARE

Ultragenyx Pharmaceutical (RARE)

Ultragenyx Pharmaceutical Inc

から:

Regulatory News

Text Search:

次の項目別のソート:

Non-Regulatory News

Showing the most relevant articles for your search:NASDAQ:RARE

1 2 3 4 5 6 7 8 9 10 次へ >>

日付	受信時刻	ニュースソース	見出し	コード	企業名
2024/05/18	05 : 30	GlobeNewswire Inc.	Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)	NASDAQ:RARE	Ultragenyx Pharmaceutical Inc
2024/05/08	05 : 30	GlobeNewswire Inc.	Ultragenyx to Participate at Bank of America’s 2024 Healthcare Conference	NASDAQ:RARE	Ultragenyx Pharmaceutical Inc
2024/05/03	05 : 00	GlobeNewswire Inc.	Ultragenyx Reports First Quarter 2024 Financial Results and Corporate Update	NASDAQ:RARE	Ultragenyx Pharmaceutical Inc
2024/05/01	05 : 00	GlobeNewswire Inc.	Ultragenyx Issues 2023 Corporate Responsibility Report, Showcasing Commitment to Improving Equity and Access to Innovation in Rare Disease	NASDAQ:RARE	Ultragenyx Pharmaceutical Inc
2024/04/30	21 : 00	GlobeNewswire Inc.	Ultragenyx Announces Completion of Enrollment in Phase 3 Orbit and Cosmic Studies Evaluating Setrusumab (UX143) for the Treatment of Osteogenesis Imperfecta (OI)	NASDAQ:RARE	Ultragenyx Pharmaceutical Inc
2024/04/26	05 : 30	GlobeNewswire Inc.	Ultragenyx to Host Conference Call for First Quarter 2024 Financial Results and Corporate Update	NASDAQ:RARE	Ultragenyx Pharmaceutical Inc
2024/04/20	05 : 30	GlobeNewswire Inc.	Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)	NASDAQ:RARE	Ultragenyx Pharmaceutical Inc
2024/04/15	20 : 00	GlobeNewswire Inc.	Ultragenyx Announces Positive Interim Phase 1/2 Data in Patients with Angelman Syndrome After Treatment with GTX-102	NASDAQ:RARE	Ultragenyx Pharmaceutical Inc
2024/04/13	05 : 22	GlobeNewswire Inc.	Ultragenyx Announces Update to Conference Call Timing to Discuss New Data from GTX-102 in Patients with Angelman Syndrome	NASDAQ:RARE	Ultragenyx Pharmaceutical Inc
2024/04/12	21 : 00	GlobeNewswire Inc.	Ultragenyx Announces Upcoming Data Presentations at American Academy of Neurology (AAN) 2024 Annual Meeting	NASDAQ:RARE	Ultragenyx Pharmaceutical Inc
2024/03/23	05 : 00	GlobeNewswire Inc.	Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)	NASDAQ:RARE	Ultragenyx Pharmaceutical Inc
2024/03/06	10 : 23	Edgar (US Regulatory)	Form 4 - Statement of changes in beneficial ownership of securities	NASDAQ:RARE	Ultragenyx Pharmaceutical Inc
2024/03/06	10 : 22	Edgar (US Regulatory)	Form 4 - Statement of changes in beneficial ownership of securities	NASDAQ:RARE	Ultragenyx Pharmaceutical Inc
2024/03/06	10 : 17	Edgar (US Regulatory)	Form 4 - Statement of changes in beneficial ownership of securities	NASDAQ:RARE	Ultragenyx Pharmaceutical Inc
2024/03/06	10 : 15	Edgar (US Regulatory)	Form 4 - Statement of changes in beneficial ownership of securities	NASDAQ:RARE	Ultragenyx Pharmaceutical Inc
2024/03/06	10 : 13	Edgar (US Regulatory)	Form 4 - Statement of changes in beneficial ownership of securities	NASDAQ:RARE	Ultragenyx Pharmaceutical Inc
2024/03/06	10 : 10	Edgar (US Regulatory)	Form 4 - Statement of changes in beneficial ownership of securities	NASDAQ:RARE	Ultragenyx Pharmaceutical Inc
2024/03/06	10 : 08	Edgar (US Regulatory)	Form 4 - Statement of changes in beneficial ownership of securities	NASDAQ:RARE	Ultragenyx Pharmaceutical Inc
2024/02/28	06 : 30	GlobeNewswire Inc.	Ultragenyx to Participate at Investor Conferences in March	NASDAQ:RARE	Ultragenyx Pharmaceutical Inc
2024/02/24	06 : 05	GlobeNewswire Inc.	Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)	NASDAQ:RARE	Ultragenyx Pharmaceutical Inc
2024/02/22	07 : 03	Edgar (US Regulatory)	Form S-3ASR - Automatic shelf registration statement of securities of well-known seasoned issuers	NASDAQ:RARE	Ultragenyx Pharmaceutical Inc
2024/02/16	06 : 04	Edgar (US Regulatory)	Form 8-K - Current report	NASDAQ:RARE	Ultragenyx Pharmaceutical Inc
2024/02/16	06 : 01	GlobeNewswire Inc.	Ultragenyx Reports Fourth Quarter and Full Year 2023 Financial Results and Corporate Update	NASDAQ:RARE	Ultragenyx Pharmaceutical Inc
2024/02/09	06 : 00	GlobeNewswire Inc.	Ultragenyx to Host Conference Call for Fourth Quarter and Full-Year 2023 Financial Results and Corporate Update	NASDAQ:RARE	Ultragenyx Pharmaceutical Inc
2024/02/06	22 : 00	GlobeNewswire Inc.	Ultragenyx Announces Data Demonstrating Treatment with UX111 Results in Significant Reduction in Heparan Sulfate Exposure in Cerebrospinal Fluid Correlated with Improved Long-term Cognitive Function in Patients with Sanfilippo Syndrome Type A (MPS IIIA)	NASDAQ:RARE	Ultragenyx Pharmaceutical Inc
2024/02/06	06 : 05	GlobeNewswire Inc.	Ultragenyx Receives PRIME Designation from European Medicines Agency (EMA) for GTX-102 for the Treatment of Angelman Syndrome	NASDAQ:RARE	Ultragenyx Pharmaceutical Inc
2024/01/26	06 : 05	GlobeNewswire Inc.	Ultragenyx Announces Completion of Dosing Across Stage 1 Cohorts in Pivotal Phase 1/2/3 Cyprus2+ Study Evaluating UX701 Gene Therapy for the Treatment of Wilson Disease	NASDAQ:RARE	Ultragenyx Pharmaceutical Inc
2024/01/20	06 : 00	GlobeNewswire Inc.	Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)	NASDAQ:RARE	Ultragenyx Pharmaceutical Inc
2024/01/08	21 : 00	GlobeNewswire Inc.	Mereo BioPharma Provides Update on Pipeline Progress and Corporate Developments	NASDAQ:RARE	Ultragenyx Pharmaceutical Inc
2024/01/08	20 : 03	Edgar (US Regulatory)	Form 8-K - Current report	NASDAQ:RARE	Ultragenyx Pharmaceutical Inc

Showing the most relevant articles for your search:NASDAQ:RARE

1 2 3 4 5 6 7 8 9 10 次へ >>

Morgan Stanley Finance L...

State Street Global Advi...

Xcite Resources

Constellation Resources

Arcane Crypto AB (CE)

Perpetual Trust Services

Goldman Sachs S&P 500 Co...

Delayed Upgrade Clock

顧客サポート: +44 (0) 203 8794 460 | support@advfn.com

ADVFNのサービスをご利用いただくには、利用規約